接受心脏支架治疗的合并冠心病的肝硬化患者消化道出血发生率高但死亡率未增加
该研究利用机构数据库识别2000年1月至2015年9月间148例合并冠心病的肝硬化患者,68例接受支架治疗、80例接受药物治疗。支架组1年消化道出血发生率22.1% vs 药物组5%(P=.003),2年27.9% vs 5%(P=.0002),全因死亡率相似(20.6% vs 21.3%)。多因素分析显示质子泵抑制剂(PPI)对消化道出血有高度保护作用(OR=0.26,95%CI=0.08-0.79)。
要点
- 支架组1年消化道出血发生率22.1% vs 药物组5%(P=.003),2年27.9% vs 5%(P=.0002)。
- 支架组与药物组全因死亡率相似(20.6% vs 21.3%)。
- 多因素分析显示PPI使用对消化道出血有高度保护作用(OR=0.26,95%CI=0.08-0.79)。
核心结论
- 在本研究中心的肝硬化患者中,支架治疗冠心病与消化道出血风险显著增加相关,但对生存无不良影响。
- 作者认为,尽管支架的心血管获益是否超过消化道出血风险仍不明确,但研究结果提示不应因担心消化道出血而拒绝给支架置入的肝硬化患者使用双联抗血小板治疗(DAPT)。
- 作者建议应强烈考虑使用PPI。
研究设计与样本
- 利用机构数据库识别2000年1月至2015年9月间合并冠心病的肝硬化患者,接受支架治疗者为病例组,接受药物治疗者为对照组。
- 共纳入148例合并冠心病的肝硬化患者,其中68例接受支架治疗(病例组),80例接受药物治疗(对照组)。
- 主要结局为消化道出血和死亡率。
主要发现
- 病例组与对照组在人口学特征、合并症、MELD评分和临床表现方面相似;DAPT使用率病例组为98.5%,对照组为5%。
- 消化道出血发生率病例组显著高于对照组:1年时为22.1% vs 5%(P=.003),2年时为27.9% vs 5%(P=.0002)。
- 全因死亡率两组相似:病例组20.6% vs 对照组21.3%。
- 无患者因消化道出血需要手术或血管造影,无已知患者因消化道出血死亡。
- 多因素分析显示使用质子泵抑制剂(PPI)对消化道出血有高度保护作用(OR=0.26,95%CI=0.08-0.79)。
关键数值与推荐
- 消化道出血发生率:支架组1年22.1% vs 药物组5%(P=.003),2年27.9% vs 5%(P=.0002)。
- 全因死亡率:支架组20.6% vs 药物组21.3%。
- DAPT使用率:支架组98.5% vs 药物组5%。
- PPI对消化道出血的保护作用:OR=0.26(95%CI=0.08-0.79)。
临床怎么用
- 作者认为,不应因担心消化道出血而拒绝给支架置入的肝硬化患者使用DAPT。
- 作者建议应强烈考虑使用PPI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with coronary artery disease (CAD) treated with stents require dual antiplatelet therapy (DAPT). For cirrhotics, who often have varices and coagulopathy, it is not clear if the risk of gastrointestinal bleeding (GIB) should preclude use of DAPT. AIM: To compare GIB and mortality rates in cirrhotics with CAD treated medically or with stents. METHODS: Using institutional databases, we identified patients with cirrhosis and CAD treated with stents or medical therapy between January 2000-September 2015. Primary outcomes were GIB and mortality. RESULTS: We identified 148 cirrhotics with CAD; 68 received stents (cases), 80 were treated with medical therapy (controls). Cases and controls had similar demographics, comorbidities, MELD scores and clinical presentation; DAPT was used in 98.5% of cases vs 5% of controls. The incidence of GIB was significantly higher in cases than controls (22.1% vs 5% at 1 year, P=.003; 27.9% vs 5% at 2 years, P=.0002), whereas all-cause mortality was similar (20.6% vs 21.3%). No patient required surgery or angiography for GIB, and no known patients died due to GIB. Multivariate analysis revealed use of a proton pump inhibitor (PPI) was highly protective against GIB (OR=0.26, 95%CI=0.08-0.79). CONCLUSIONS: CAD treatment with stents in our cirrhotics was associated with a significantly increased risk of GIB, but no adverse effects on survival. Although it remains unclear whether the cardiovascular benefits of stents outweigh the GIB risk, our findings suggest that DAPT should not be withheld from stented cirrhotics for fear of GIB. Moreover, the use of a PPI should be strongly considered.
引用
- Krill T, Brown G, Weideman RA, et al. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality. Aliment Pharmacol Ther. 2017. PMID: 28488370. doi:10.1111/apt.14121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。